COVID-19疫苗接种与异常子宫出血风险:全国性自身对照病例系列研究
该研究利用韩国全国数据库,纳入16-64岁接种首剂COVID-19疫苗后180天内新诊断异常子宫出血(AUB)的女性83422例,采用自身对照病例系列分析。结果显示首剂接种后14天内需医院诊疗的AUB风险轻度升高(IRR 1.04,95%CI 1.02-1.06),首剂后各风险区间均升高,第二、三剂后未见显著增加。
要点
- 首剂接种后14天内AUB就诊风险轻度升高(IRR 1.04,95%CI 1.02-1.06)。
- 首剂后14、21、28天风险区间IRR分别为1.12、1.08、1.07。
- 第二剂和第三剂后未见AUB风险显著增加。
核心结论
- 首剂COVID-19疫苗接种后需医院诊疗的异常子宫出血风险轻度升高,但后续剂次该趋势减弱,未见显著风险增加。
- 作者指出解释这些发现时应考虑影响异常阴道或子宫出血就医行为的因素。
研究设计与样本
- 全国性自身对照病例系列研究,使用韩国COVID-19登记数据与国民健康保险服务理赔数据库。
- 纳入16-64岁接种首剂疫苗后180天内在住院或门诊新诊断AUB的女性,共83422例。
- 估计各剂次后1-14、1-21、1-28天风险期的发生率比(IRR),与基线期(首剂后1-180天排除风险期)比较;仅考虑观察期内首次事件。
主要发现
- 首剂接种后14天内需医院诊疗的AUB风险较基线期轻度升高(IRR 1.04,95%CI 1.02-1.06)。
- 首剂后14天风险期IRR 1.12(95%CI 1.09-1.15),21天风险期IRR 1.08(95%CI 1.06-1.10),28天风险期IRR 1.07(95%CI 1.05-1.09)。
- 第二剂和第三剂后未见显著增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between COVID-19 vaccination and the risk of the abnormal uterine bleeding (AUB) specifically focusing on vaginal or uterine bleeding that requires hospital care in women. METHODS: We used a nationwide database in the Republic of Korea that combined COVID-19 registry data, which contains information on COVID-19 vaccination, with the claims database of the National Health Insurance Service. We included women aged 16-64 who received their first vaccine dose and were newly diagnosed with AUB in inpatient or outpatient settings within 180 days after receiving the first dose. A population-based self-controlled case series analysis was used to estimate the incidence rate ratio (IRR) during the risk periods, including 1-14, 1-21, and 1-28 days after each vaccine dose, compared to the baseline period. The baseline period was defined as the period of 1-180 days following the first vaccine dose, excluding the periods that corresponds to the risk periods. To address the SCCS assumption violation from recurrent nature, only the first event during the observation period was considered. RESULTS: Among 83,422 eligible patients, the risk of AUB requiring hospital care within 14 days following COVID-19 vaccination was slightly elevated compared to the baseline period (IRR 1.04, 95 % CI 1.02-1.06). The risk was notably higher after the first dose, regardless of the risk interval (14-day risk period: IRR 1.12, 95 % CI 1.09-1.15; 21-day risk period: IRR 1.08, 95 % CI 1.06-1.10; 28-day risk period: IRR 1.07, 95 % CI 1.05-1.09). No significant increase was observed after the second and third doses. CONCLUSION: This study found a modest increase in healthcare utilization for AUB after the first dose of COVID-19 vaccination. However, this trend diminished with subsequent doses, showing no significantly increased risk. These findings should be interpreted while considering factors that influence healthcare-seeking behavior for unexpected vaginal or uterine bleeding.
引用
- Jeong NY, Cho S, Lim E, et al. COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study. Vaccine. 2025. PMID: 40818314. doi:10.1016/j.vaccine.2025.127619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。